Nuvation BioNUVB
NUVB
About: Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Employees: 220
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
75% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 36
32% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 22
23% more capital invested
Capital invested by funds: $429M [Q3] → $526M (+$97.3M) [Q4]
3% more funds holding
Funds holding: 154 [Q3] → 159 (+5) [Q4]
2.68% more ownership
Funds ownership: 56.07% [Q3] → 58.74% (+2.68%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]
100% less call options, than puts
Call options by funds: $3K | Put options by funds: $952K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
178%
upside
Avg. target
$8.67
301%
upside
High target
$10
363%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Silvan Tuerkcan 20% 1-year accuracy 10 / 51 met price target | 178%upside $6 | Market Outperform Initiated | 23 Apr 2025 |
Jones Trading Soumit Roy 15% 1-year accuracy 2 / 13 met price target | 363%upside $10 | Buy Initiated | 12 Mar 2025 |
HC Wainwright & Co. Robert Burns 24% 1-year accuracy 41 / 173 met price target | 363%upside $10 | Buy Maintained | 10 Mar 2025 |
Financial journalist opinion
Neutral
Business Wire
6 days ago
Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on solving some of the toughest challenges in cancer treatment, will announce results for the first quarter of 2025 on Wednesday, May 7, 2025. Company executives will provide an overview of its programs, summarize its commercial strategy for taletrectinib, and review financial results beginning at 4:30 p.m. ET. The U.S. Food and Drug Administration assigned taletrectinib's New Drug Application with a Pr.
Neutral
Business Wire
3 weeks ago
Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025, at 10:00 a.m. PT/1:00 p.m. ET in Las Vegas, NV. An audio.
Neutral
Business Wire
1 month ago
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for taletrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25–30, 2025 in Chicago, Illinois. Presentation Overview: Title: Taletrectinib, a next generation selective ROS1 inhibitor,.
Neutral
Business Wire
1 month ago
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be reported in a mini oral presentation at the European Lung Cancer Congress taking place March 26–29, 2025 in Paris, France. Mini Oral Presentation Overview: Ti.
Neutral
Business Wire
1 month ago
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “Nuvation Bio had a transformative year in 2024, marked by significant milestones. We acquired AnHeart Therapeutics, reported positive pivotal data for taletrectinib, and submitted the NDA for taletrectinib, which was accep.
Neutral
Business Wire
1 month ago
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced non-dilutive financings of up to $250 million with Sagard Healthcare Partners (Sagard). The transaction comprises a royalty interest financing of $150 million and a senior term loan of up to $100 million. These financings strengthen Nuvation Bio's balance sheet to fully fund commercialization of taletrectinib in the U.S., if approve.
Neutral
Business Wire
2 months ago
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, MA. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investo.
Neutral
PRNewsWire
2 months ago
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Positive
Seeking Alpha
2 months ago
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Application for the drug, assigning it priority review and a PDUFA date of June 23, 2025. Taletrectinib shows clearly superior clinical data compared to rivals, with a potential market opportunity of ~$3.8bn by its fourth year, despite current market skepticism.
Neutral
Business Wire
2 months ago
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access Program (EAP) for taletrectinib in the U.S. for the treatment of patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) when no comparable or satisfactory alternative therapy options are available. “This EAP reflects our unwavering dedication to patie.
Charts implemented using Lightweight Charts™